瓶颈
生物制药
生化工程
单克隆抗体
生物过程
生产力
生物技术
过程开发
新兴技术
业务
风险分析(工程)
计算机科学
工程类
生物
抗体
经济
过程管理
免疫学
人工智能
嵌入式系统
宏观经济学
化学工程
作者
Nripen Singh,Abhiram Arunkumar,Srinivas Chollangi,Zhijun Tan,Michael Borys,Zheng Jian Li
摘要
Considerable progress has been made increasing productivity of cell cultures to meet the rapidly growing demand for antibody biopharmaceuticals through increased cell densities and longer culture times. This in turn has dramatically increased the burden of process and product related impurities on the purification processes. In addition, current trends in the biopharmaceutical industry point toward both increased productivity and targeting smaller patient populations for new indications. Taken together, these developments are driving the industry to explore alternative separation technologies as a future manufacturing strategy. Clarification technologies well established in other industries, such as flocculation and precipitation are increasingly considered as a viable solution to address this bottleneck in antibody processes. However, several technical issues need to be fully addressed including suitability as a platform application, robustness, process cost, toxicity, and clearance. This review will focus on recent efforts to incorporate new generation clarification technologies for mammalian cell cultures producing monoclonal antibodies as well as challenges to their implementation supported by a case study.
科研通智能强力驱动
Strongly Powered by AbleSci AI